HomeCompareESALY vs EPRT

ESALY vs EPRT: Dividend Comparison 2026

ESALY yields 31.26% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESALY wins by $235.3K in total portfolio value
10 years
ESALY
ESALY
● Live price
31.26%
Share price
$61.51
Annual div
$19.23
5Y div CAGR
7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298.7K
Annual income
$71,135.45
Full ESALY calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ESALY vs EPRT

📍 ESALY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALY + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALY
Annual income on $10K today (after 15% tax)
$2,657.23/yr
After 10yr DRIP, annual income (after tax)
$60,465.13/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ESALY beats the other by $49,550.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALY + EPRT for your $10,000?

ESALY: 50%EPRT: 50%
100% EPRT50/50100% ESALY
Portfolio after 10yr
$181.0K
Annual income
$41,988.08/yr
Blended yield
23.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ESALY
No analyst data
Altman Z
5.1
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALY buys
0
EPRT buys
0
No recent congressional trades found for ESALY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALYEPRT
Forward yield31.26%3.92%
Annual dividend / share$19.23$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7%29%
Portfolio after 10y$298.7K$63.4K
Annual income after 10y$71,135.45$12,840.73
Total dividends collected$238.7K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ESALY vs EPRT ($10,000, DRIP)

YearESALY PortfolioESALY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$14,045$3,344.99$11,205$505.18+$2.8KESALY
2$19,726$4,698.03$12,672$682.46+$7.1KESALY
3$27,705$6,598.37$14,490$930.48+$13.2KESALY
4$38,912$9,267.41$16,786$1,282.69+$22.1KESALY
5$54,652$13,016.06$19,753$1,791.56+$34.9KESALY
6$76,759$18,281.04$23,677$2,541.64+$53.1KESALY
7$107,808$25,675.69$29,008$3,672.99+$78.8KESALY
8$151,416$36,061.47$36,463$5,425.08+$115.0KESALY
9$212,663$50,648.29$47,238$8,221.57+$165.4KESALY
10$298,685$71,135.45$63,385$12,840.73+$235.3KESALY

ESALY vs EPRT: Complete Analysis 2026

ESALYStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALY Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ESALY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALY vs SCHDESALY vs JEPIESALY vs OESALY vs KOESALY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.